Bafna Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Bafna Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 18.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt
Aug 15Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking
Feb 13The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business
Nov 19Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?
Dec 10In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bafna Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 1,533 | 113 | N/A | N/A | N/A |
9/30/2023 | 1,591 | 172 | 98 | 155 | N/A |
6/30/2023 | 1,404 | 163 | N/A | N/A | N/A |
3/31/2023 | 1,153 | 113 | -33 | 50 | N/A |
12/31/2022 | 881 | 50 | N/A | N/A | N/A |
9/30/2022 | 743 | 37 | -113 | 3 | N/A |
6/30/2022 | 808 | 44 | N/A | N/A | N/A |
3/31/2022 | 851 | 52 | 22 | 97 | N/A |
12/31/2021 | 920 | 88 | N/A | N/A | N/A |
9/30/2021 | 890 | 80 | -38 | 28 | N/A |
6/30/2021 | 758 | 61 | N/A | N/A | N/A |
3/31/2021 | 712 | 58 | -197 | -136 | N/A |
12/31/2020 | 625 | 256 | N/A | N/A | N/A |
9/30/2020 | 551 | 28 | -419 | -389 | N/A |
6/30/2020 | 523 | 18 | N/A | N/A | N/A |
3/31/2020 | 425 | -19 | -357 | -343 | N/A |
12/31/2019 | 522 | -394 | N/A | N/A | N/A |
9/30/2019 | 421 | -178 | N/A | N/A | N/A |
6/30/2019 | 404 | -196 | N/A | N/A | N/A |
3/31/2019 | 436 | -199 | -21 | -18 | N/A |
3/31/2018 | 480 | -167 | -72 | -70 | N/A |
3/31/2017 | 655 | -191 | N/A | -9 | N/A |
3/31/2016 | 863 | -140 | N/A | 9 | N/A |
3/31/2015 | 1,017 | 62 | N/A | 107 | N/A |
3/31/2014 | 1,861 | 14 | N/A | 16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BAFNAPH's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if BAFNAPH's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if BAFNAPH's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BAFNAPH's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if BAFNAPH's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BAFNAPH's Return on Equity is forecast to be high in 3 years time